BPC-157

What BPC-157 Is

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide: a chain of 15 amino acids with the sequence GEPPPGKPADDAGLV. It is described as a partial, stabilized fragment derived from a larger protein, BPC, that was identified in human gastric juice. The molecule was characterized in the early 1990s by the laboratory of Predrag Sikiric at the University of Zagreb, which has authored the majority of the published literature on it. A frequently noted property is its reported stability in gastric acid, unusual for a peptide, which motivated study of both oral and injectable routes in animal experiments. It is important to distinguish BPC-157 from FDA-approved peptide drugs such as semaglutide or tirzepatide: BPC-157 is not an approved medicine, and essentially all of its evidence base is preclinical.

Mechanism of Action

The proposed mechanisms are drawn from rodent and cell-culture studies and converge on tissue protection and blood-vessel formation rather than a single confirmed receptor. A central theme is angiogenesis: research indicates BPC-157 up-regulates and activates VEGFR2, engaging the Akt-eNOS pathway to increase nitric oxide, as described by Hsieh and colleagues (Journal of Molecular Medicine, 2017) and by later work implicating a Src-Caveolin-1-eNOS route in vascular tissue. In tendon fibroblasts, Chang and colleagues (Journal of Applied Physiology, 2011) reported that BPC-157 dose-dependently raised phosphorylation of focal adhesion kinase (FAK) and paxillin, drivers of cell migration and adhesion, and improved cell survival under oxidative stress. Other preclinical reports describe effects on nitric-oxide balance and neurotransmitter systems. No definitive human mechanism has been established.

What Published Research Has Examined

The research record is broad but almost entirely preclinical. Musculoskeletal repair is a major theme: Krivic and colleagues (Journal of Orthopaedic Research, 2006) reported improved Achilles tendon-to-bone healing in rats, with better biomechanical strength and collagen organization and resistance to corticosteroid-induced impairment, and Cerovecki and colleagues (Journal of Orthopaedic Research, 2010) reported improved medial collateral ligament healing. The peptide's original domain is gastrointestinal cytoprotection, with rodent studies in ulcer, NSAID-injury, and colitis models. Angiogenesis-focused work has examined wound healing and hind-limb ischemia. There is also exploratory rodent literature spanning nerve, muscle, bone, and various organ-injury contexts, much of it from the Zagreb group and collaborators.

Key Findings and Evidence Level

Taken together, the preclinical findings are consistent in direction: across multiple rodent and in-vitro models, BPC-157 has been associated with accelerated tissue repair, cytoprotection of the gut lining, and enhanced angiogenesis. However, the evidence tier is firmly preclinical. There are no completed, published randomized controlled trials demonstrating efficacy in humans, and much of the corpus originates from a small cluster of related research groups, which reviewers cite as a limitation for independent replication. Interest in fitness and recovery communities has outpaced the clinical data; the honest scientific summary is promising animal data with unresolved human translation.

Regulatory Status

As of July 2026, BPC-157 is not FDA approved and is classified as Category 2, meaning compounding pharmacies may not currently compound it due to insufficient safety data or significant concern. It is one of exactly seven compounds on the FDA Pharmacy Compounding Advisory Committee (PCAC) docket for the meeting on July 23-24, 2026, alongside TB-500, KPV, MOTS-c, emideltide, epitalon, and semax. The committee will vote on whether to recommend adding these to the 503A Bulks List. That vote is non-binding and represents roughly the second of about six steps in FDA rulemaking; even a unanimous favorable vote would not by itself make BPC-157 legal to compound, and a realistic timeline to actual legal compounding availability is at least 12 to 18 months after a favorable vote.

Safety Considerations and Related Compounds

Published safety data are largely limited to short-term rodent studies, which generally report low acute toxicity; long-term human safety, pharmacokinetics, and immunogenicity are not well characterized, and no completed human safety trials have been published. Reviewers, including FDA briefing materials prepared for the July 2026 review, note that the substance is not well characterized and that human safety data, including immunogenicity, are insufficient; the literature also raises a theoretical concern that a pro-angiogenic agent could influence existing tumor vasculature, an open question rather than a demonstrated effect. Material sourced outside a regulated setting also raises purity and sterility concerns. Compounds frequently discussed alongside BPC-157 in the tissue-repair and recovery literature include TB-500 (a thymosin beta-4 fragment, also on the July 2026 PCAC docket), KPV, GHK-Cu, and MOTS-c. None of this constitutes medical advice; it summarizes the state of published research only.

Key published studies

Regulatory status

Current status: Category 2 · PCAC July 2026 docket. Not FDA approved. PepSense tracks FDA filings and updates this record as the regulatory picture changes. See the FDA PCAC tracker for the July 2026 vote and what happens next.

Related compounds

Read our full guide on whether peptides are safe.